As oral GLP-1 agonists (semaglutide, tirzepatide) gain adoption for weight loss, the beauty and aesthetics market is experiencing a structural shift in demand. Practices are reporting reduced volume in traditional body-sculpting procedures (liposuction, CoolSculpting, Emsculpt) and altered filler patterns—patients losing weight often deplete facial volume, requiring different injection strategies and timing.
Market
GLP-1 Pill Era Is Forcing Beauty Market Shift
Oral semaglutide adoption is reshaping filler and body-sculpting demand patterns.
GLP-1 adoption is forcing a recalibration of service mix and patient education.
The shift is not uniform: high-end practices report sustained demand for facial rejuvenation and skin tightening, while mid-market practices see compression in body-contouring revenue. For practice owners, the implication is clear: GLP-1 adoption is forcing a recalibration of service mix and patient education. Practices should prepare for increased demand for volume restoration (biostimulators, strategic HA placement) and skin-quality procedures (RF microneedling, chemical peels) among GLP-1 users. Practices that pivot quickly to this demographic will capture margin; those clinging to traditional body-sculpting volume will face headwinds.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.